Christenson J T, Simonet F, Badel P, Schmuziger M
Department of Cardiovascular Surgery, Hôpital de la Tour, Meyrin-Geneva, Switzerland.
Ann Thorac Surg. 1999 Sep;68(3):934-9. doi: 10.1016/s0003-4975(99)00687-6.
Beneficial effects of preoperative intraaortic balloon pump (IABP) treatment, on outcome and cost, in high-risk patients who have coronary artery bypass grafting have been demonstrated. We conducted a prospective, randomized study to determine the optimal timing for preoperative IABP support in a cohort of high-risk patients.
Sixty consecutive high-risk patients who had coronary artery bypass grafting (presenting with two or more of the following criteria: left ventricular ejection fraction less than 0.30, unstable angina, reoperation, or left main stenosis greater than 70%) entered the study. Thirty patients did not receive preoperative IABP (controls), 30 patients had preoperative IABP therapy starting 2 hours (T2), 12 hours (T12), or 24 hours (T24), by random assignment, before the operation. Fifty patients had preoperative left ventricular ejection fraction mean, less than 0.30 (less than 0.26+/-0.08), (n = 40) unstable angina, 28% (n = 17) left main stenosis, and 32% (n = 19) were reoperations.
Cardiopulmonary bypass was shorter in the IABP groups. There was one death in the IABP group and six in the control group. The complication rate for IABP was 8.3% (n = 5) without group differences. Cardiac index was significantly higher postoperatively (p<0.001) in patients with preoperative IABP treatment compared with controls. There were no significant differences between the three IABP subgroups at any time. The incidence of postoperative low cardiac output was significantly lower in the IABP groups (p<0.001). Intubation time, length of stay in the intensive care unit and the hospital was shorter in the IABP groups (p = 0.211, p<0.001, and p = 0.002, respectively). There were no differences between the IABP subgroups in any of the studied variables.
The beneficial effect of preoperative IABP in high-risk patients who have coronary artery bypass grafting was confirmed. There were no differences in outcome between the subgroups; therefore, at 2 hours preoperatively, IABP therapy can be started.
术前主动脉内球囊反搏(IABP)治疗对接受冠状动脉旁路移植术的高危患者的预后和成本具有有益影响,这已得到证实。我们进行了一项前瞻性随机研究,以确定高危患者队列中术前IABP支持的最佳时机。
连续60例接受冠状动脉旁路移植术的高危患者(符合以下两项或更多标准:左心室射血分数低于0.30、不稳定型心绞痛、再次手术或左主干狭窄大于70%)进入研究。30例患者未接受术前IABP(对照组),30例患者在手术前随机分配接受术前IABP治疗,分别在术前2小时(T2组)、12小时(T12组)或24小时(T24组)开始治疗。50例患者术前左心室射血分数平均低于0.30(低于0.26±0.08),40例(占28%)有不稳定型心绞痛,17例(占28%)有左主干狭窄,19例(占32%)为再次手术患者。
IABP组的体外循环时间较短。IABP组有1例死亡,对照组有6例死亡。IABP组的并发症发生率为8.3%(n = 5),各亚组间无差异。与对照组相比,术前接受IABP治疗的患者术后心脏指数显著更高(p<0.001)。三个IABP亚组在任何时间均无显著差异。IABP组术后低心排血量的发生率显著更低(p<0.001)。IABP组的气管插管时间、重症监护病房住院时间和住院时间更短(分别为p = 0.211、p<0.001和p = 0.002)。IABP亚组在任何研究变量上均无差异。
术前IABP对接受冠状动脉旁路移植术的高危患者的有益作用得到证实。各亚组的预后无差异;因此,可在术前2小时开始IABP治疗。